Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Egbert F Smit

Showing results (281-290 of 320) with videos related to

Pageof 32
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 23, 2015
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF CohortOliver Gautschi, Julie Milia, Bastien Cabarrou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2015
Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohortJulien Mazières, Gérard Zalcman, Lucio Crinò, et al.
The New England Journal of Medicine|April 15, 2026
First-Line Zongertinib in Advanced <i>HER2</i>-Mutant Non-Small-Cell Lung CancerJohn V Heymach, Noboru Yamamoto, Nicolas Girard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2017
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II TrialDong-Wan Kim, Marcello Tiseo, Myung-Ju Ahn, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 28, 2003
Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS studyPaul Verboom, Harm van Tinteren, Otto S Hoekstra, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|June 4, 2023
Blood platelet RNA profiles do not enable for nivolumab response prediction at baseline in patients with non-small cell lung cancerMirte Muller, Myron G Best, Vincent van der Noort, et al.
JTO Clinical and Research Reports|September 6, 2022
Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory <i>ALK</i>+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) TrialsScott N Gettinger, Rudolf M Huber, Dong-Wan Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2023
Trastuzumab Deruxtecan in Patients With <i>HER2</i>-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 TrialKoichi Goto, Yasushi Goto, Toshio Kubo, et al.
Clinical Lung Cancer|May 19, 2018
Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and TechnologiesFred R Hirsch, Keith M Kerr, Paul A Bunn, et al.
The Lancet Regional Health. Europe|March 11, 2024
Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access ProtocolKarlijn Verkerk, Birgit S Geurts, Laurien J Zeverijn, et al.
Pageof 32

Showing results (281-290 of 320) with videos related to

Sort By:
Pageof 32
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 23, 2015
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF CohortOliver Gautschi, Julie Milia, Bastien Cabarrou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2015
Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohortJulien Mazières, Gérard Zalcman, Lucio Crinò, et al.
The New England Journal of Medicine|April 15, 2026
First-Line Zongertinib in Advanced <i>HER2</i>-Mutant Non-Small-Cell Lung CancerJohn V Heymach, Noboru Yamamoto, Nicolas Girard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2017
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II TrialDong-Wan Kim, Marcello Tiseo, Myung-Ju Ahn, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 28, 2003
Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS studyPaul Verboom, Harm van Tinteren, Otto S Hoekstra, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|June 4, 2023
Blood platelet RNA profiles do not enable for nivolumab response prediction at baseline in patients with non-small cell lung cancerMirte Muller, Myron G Best, Vincent van der Noort, et al.
JTO Clinical and Research Reports|September 6, 2022
Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory <i>ALK</i>+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) TrialsScott N Gettinger, Rudolf M Huber, Dong-Wan Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2023
Trastuzumab Deruxtecan in Patients With <i>HER2</i>-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 TrialKoichi Goto, Yasushi Goto, Toshio Kubo, et al.
Clinical Lung Cancer|May 19, 2018
Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and TechnologiesFred R Hirsch, Keith M Kerr, Paul A Bunn, et al.
The Lancet Regional Health. Europe|March 11, 2024
Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access ProtocolKarlijn Verkerk, Birgit S Geurts, Laurien J Zeverijn, et al.
Pageof 32